Healthcare / Drug Manufacturers - General
Exclusive insider sentiment analysis for the Drug Manufacturers - General sector. Track real-time Director purchases and institutional money flow to identify high-conviction opportunities before the market reacts.
| Filing Date | Trade Date | Ticker | Company Name | Reporting Person | Relationship | Industry | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-07-16 22:08 | 2026-07-15 | GILD | GILEAD SCIENCES, INC. | Dickinson Andrew D | Officer; Chief Financial Officer | Drug Manufacturers - General | SALE | $129.93 | 3,000 | $389,777 | 168,646 | -1.7% |
| 2026-07-16 20:54 | 2026-07-15 | GILD | GILEAD SCIENCES, INC. | Mercier Johanna | Officer; Chief Comm & Corp Aff Officer | Drug Manufacturers - General | SALE | $129.92 | 3,000 | $389,758 | 121,234 | -2.4% |
| 2026-07-02 20:14 | 2026-07-01 | GILD | GILEAD SCIENCES, INC. | O'Day Daniel Patrick | Director, Officer; Chairman & CEO | Drug Manufacturers - General | SALE | $126.29 | 15,000 | $1,894,400 | 607,133 | -2.4% |
| 2026-06-22 11:12 | 2026-06-17 | NSRX | Nasus Pharma Ltd | Teleman Dan Benjamin | Director, Officer; Chief Executive Officer | Drug Manufacturers - General | BUY | $3.10 | 6,550 | $20,305 | 163,541 | +4.2% |
| 2026-06-16 21:53 | 2026-06-15 | GILD | GILEAD SCIENCES, INC. | Dickinson Andrew D | Officer; Chief Financial Officer | Drug Manufacturers - General | SALE | $125.40 | 3,000 | $376,200 | 171,646 | -1.7% |
| 2026-06-16 22:02 | 2026-06-15 | GILD | GILEAD SCIENCES, INC. | Mercier Johanna | Officer; Chief Comm & Corp Aff Officer | Drug Manufacturers - General | SALE | $123.92 | 3,000 | $371,762 | 124,234 | -2.4% |
| 2026-06-12 21:23 | 2026-06-11 | JNJ | JOHNSON & JOHNSON | Wengel Kathryn E | Officer; EVP, Chief TO and Risk Officer | Drug Manufacturers - General | OPT+S | $241.15 | 10,000 | $2,411,500 | 114,288 | -8.0% |
| 2026-06-11 20:23 | 2026-06-10 | LLY | ELI LILLY & Co | Yuffa Ilya | Officer; EVP&Pres, LLY USA&Global Capab | Drug Manufacturers - General | SALE | $1,150.77 | 2,500 | $2,876,925 | 29,804 | -7.7% |
| 2026-06-10 23:58 | 2026-06-09 | PFE | PFIZER INC | DAMICO JENNIFER B. | Officer; SVP & Controller | Drug Manufacturers - General | SALE | $25.70 | 2,000 | $51,400 | 31,397 | -6.0% |
| 2026-06-02 22:04 | 2026-06-01 | GILD | GILEAD SCIENCES, INC. | O'Day Daniel Patrick | Director, Officer; Chairman & CEO | Drug Manufacturers - General | SALE | $131.46 | 15,000 | $1,971,846 | 617,567 | -2.4% |
| 2026-05-22 20:05 | 2026-05-20 | AZN | ASTRAZENECA PLC | Sharma Mani | Officer; See Remarks | Drug Manufacturers - General | SALE | $185.78 | 11,893 | $2,209,482 | 19,262 | -38.2% |
| 2026-05-18 21:50 | 2026-05-15 | GILD | GILEAD SCIENCES, INC. | Dickinson Andrew D | Officer; Chief Financial Officer | Drug Manufacturers - General | SALE | $132.27 | 3,000 | $396,810 | 173,191 | -1.7% |
| 2026-05-18 21:45 | 2026-05-15 | GILD | GILEAD SCIENCES, INC. | Mercier Johanna | Officer; Chief Comm & Corp Aff Officer | Drug Manufacturers - General | OPT+S | $131.29 | 28,000 | $3,676,198 | 125,779 | -18.2% |
| 2026-05-07 20:00 | 2026-05-06 | LLY | ELI LILLY & Co | LILLY ENDOWMENT INC | Other | Drug Manufacturers - General | SALE | $995.36 | 15,828 | $15,754,536 | 91,881,150 | 0.0% |
| 2026-05-07 20:00 | 2026-05-06 | OGN | Organon & Co. | Holzbaur Lynette | Officer; SVP and Corporate Controller | Drug Manufacturers - General | SALE | $13.35 | 26,448 | $353,080 | 0 | -100.0% |
| 2026-05-07 14:02 | 2026-05-06 | OGN | Organon & Co. | Holzbaur Lynette | Officer; SVP and Corporate Controller | Drug Manufacturers - General | BUY | $13.35 | 26,448 | $353,080 | 52,851 | +100.2% |
| 2026-05-06 00:09 | 2026-05-04 | AMGN | AMGEN INC | Grygiel Nancy A. | Officer; SVP & CCO | Drug Manufacturers - General | SALE | $323.73 | 1,237 | $400,451 | 7,009 | -15.0% |
| 2026-04-29 21:53 | 2026-04-28 | GILD | GILEAD SCIENCES, INC. | O'Day Daniel Patrick | Director, Officer; Chairman & CEO | Drug Manufacturers - General | SALE | $129.16 | 10,000 | $1,291,608 | 632,567 | -1.6% |
| 2026-04-23 01:44 | 2026-04-22 | NSRX | Nasus Pharma Ltd | Teleman Dan Benjamin | Director, Officer; Chief Executive Officer | Drug Manufacturers - General | BUY | $3.76 | 2,900 | $10,904 | 156,991 | +1.9% |
| 2026-04-16 22:40 | 2026-04-15 | GILD | GILEAD SCIENCES, INC. | Mercier Johanna | Officer; Chief Comm & Corp Aff Officer | Drug Manufacturers - General | SALE | $140.96 | 3,000 | $422,880 | 128,779 | -2.3% |
| 2026-04-16 22:41 | 2026-04-15 | GILD | GILEAD SCIENCES, INC. | Dickinson Andrew D | Officer; Chief Financial Officer | Drug Manufacturers - General | SALE | $140.96 | 3,000 | $422,880 | 176,191 | -1.7% |
| 2026-04-02 20:29 | 2026-04-01 | BMY | BRISTOL MYERS SQUIBB CO | Elkins David V | Officer; EVP, Chief Financial Officer | Drug Manufacturers - General | SALE | $61.67 | 30,000 | $1,850,016 | 159,248 | -15.9% |
| 2026-04-01 11:31 | 2026-03-31 | NSRX | Nasus Pharma Ltd | Teleman Dan Benjamin | Director, Officer; Chief Executive Officer | Drug Manufacturers - General | BUY | $2.04 | 15,000 | $30,600 | 21,246 | +240.2% |
| 2026-03-30 21:59 | 2026-03-27 | GILD | GILEAD SCIENCES, INC. | O'Day Daniel Patrick | Director, Officer; Chairman & CEO | Drug Manufacturers - General | SALE | $136.82 | 10,000 | $1,368,162 | 642,567 | -1.5% |
| 2026-03-17 22:56 | 2026-03-16 | GILD | GILEAD SCIENCES, INC. | Mercier Johanna | Officer; Chief Comm & Corp Aff Officer | Drug Manufacturers - General | SALE | $144.23 | 3,000 | $432,690 | 131,779 | -2.2% |
| 2026-03-17 22:14 | 2026-03-16 | GILD | GILEAD SCIENCES, INC. | Dickinson Andrew D | Officer; Chief Financial Officer | Drug Manufacturers - General | SALE | $144.23 | 3,000 | $432,690 | 179,191 | -1.6% |
| 2026-03-07 01:05 | 2026-03-04 | ABBV | AbbVie Inc. | Purdue David Ryan | Officer; SVP, Controller | Drug Manufacturers - General | SALE | $233.56 | 5,230 | $1,221,519 | 2,654 | -66.3% |
| 2026-03-04 00:21 | 2026-02-27 | JNJ | JOHNSON & JOHNSON | Decker Robert J | Officer; VP Corporate Controller | Drug Manufacturers - General | OPT+S | $247.87 | 4,075 | $1,010,070 | 23,682 | -14.7% |
| 2026-03-04 02:10 | 2026-03-02 | ABBV | AbbVie Inc. | Siatis Perry C | Officer; EVP, GC AND SECRETARY | Drug Manufacturers - General | SALE | $234.39 | 18,668 | $4,375,550 | 4,619 | -80.2% |
| 2026-03-03 00:46 | 2026-02-27 | GILD | GILEAD SCIENCES, INC. | O'Day Daniel Patrick | Director, Officer; Chairman & CEO | Drug Manufacturers - General | SALE | $144.79 | 10,000 | $1,447,859 | 642,308 | -1.5% |
| 2026-03-03 03:20 | 2026-02-26 | AMGN | Amgen Inc. | Santos Esteban | Officer; EVP, Operations | Drug Manufacturers - General | OPT+S | $379.12 | 54,792 | $20,772,595 | 76,618 | -41.7% |
| 2026-02-28 01:00 | 2026-02-25 | ABBV | AbbVie Inc. | Siatis Perry C | Officer; EVP, GC AND SECRETARY | Drug Manufacturers - General | OPT+S | $230.00 | 22,381 | $5,147,630 | 38,137 | -37.0% |
| 2026-02-24 01:20 | 2026-02-20 | JNJ | JOHNSON & JOHNSON | Schmid Timothy | Officer; EVP, WW Chair, MedTech | Drug Manufacturers - General | SALE | $245.66 | 1,322 | $324,763 | 25,447 | -4.9% |
| 2026-02-21 03:43 | 2026-02-19 | AMGN | Amgen Inc. | Busch Matthew C. | Officer; VP, Finance & CAO | Drug Manufacturers - General | SALE | $375.79 | 1,000 | $375,790 | 3,423 | -22.6% |
| 2026-02-19 01:22 | 2026-02-17 | GILD | GILEAD SCIENCES, INC. | Mercier Johanna | Officer; Chief Comm & Corp Aff Officer | Drug Manufacturers - General | OPT+S | $154.44 | 28,000 | $4,324,228 | 120,288 | -18.9% |
| 2026-02-19 05:11 | 2026-02-17 | JNJ | JOHNSON & JOHNSON | Broadhurst Vanessa | Officer; EVP, Global Corp Affairs | Drug Manufacturers - General | OPT+S | $243.39 | 6,197 | $1,508,288 | 23,003 | -21.2% |
| 2026-02-19 05:11 | 2026-02-18 | JNJ | JOHNSON & JOHNSON | Schmid Timothy | Officer; EVP, WW Chair, MedTech | Drug Manufacturers - General | OPT+S | $244.33 | 22,623 | $5,527,507 | 26,769 | -45.8% |
| 2026-02-19 05:12 | 2026-02-17 | JNJ | JOHNSON & JOHNSON | REED JOHN C | Officer; EVP, Innovative Medicine, R&D | Drug Manufacturers - General | OPT+S | $243.00 | 53,931 | $13,105,233 | 10,658 | -83.5% |
| 2026-02-19 05:12 | 2026-02-17 | JNJ | JOHNSON & JOHNSON | Wolk Joseph J | Officer; Exec VP, CFO | Drug Manufacturers - General | OPT+S | $242.80 | 89,654 | $21,767,830 | 14,000 | -86.5% |
| 2026-02-19 05:12 | 2026-02-13 | JNJ | JOHNSON & JOHNSON | Swanson James D. | Officer; EVP, CIO | Drug Manufacturers - General | OPT+S | $243.39 | 62,080 | $15,109,757 | 25,698 | -70.7% |
| 2026-02-19 01:11 | 2026-02-17 | GILD | GILEAD SCIENCES, INC. | Dickinson Andrew D | Officer; Chief Financial Officer | Drug Manufacturers - General | SALE | $154.43 | 3,000 | $463,290 | 167,779 | -1.8% |
| 2026-02-18 04:16 | 2026-02-12 | BIIB | BIOGEN INC. | Murphy Nicole | Officer; Head of Pharm Ops and Tech | Drug Manufacturers - General | BUY | $195.04 | 3 | $585 | 19,611 | +0.0% |
| 2026-02-13 00:02 | 2026-02-12 | MRK | Merck & Co., Inc. | Guindo Chirfi | Officer; Chief Marketing Officer | Drug Manufacturers - General | SALE | $121.46 | 10,000 | $1,214,562 | 60,615 | -14.2% |
| 2026-02-11 00:04 | 2026-02-10 | MRK | Merck & Co., Inc. | Li Dean Y | Officer; Executive VP & President, MRL | Drug Manufacturers - General | SALE | $117.52 | 10,235 | $1,202,844 | 92,035 | -10.0% |
| 2026-02-11 01:05 | 2026-02-09 | BIIB | BIOGEN INC. | Singhal Priya | Officer; Head of Development | Drug Manufacturers - General | OPT+S | $199.83 | 2,660 | $531,548 | 8,043 | -24.9% |
| 2026-02-10 00:01 | 2026-02-09 | MRK | Merck & Co., Inc. | Zachary Jennifer | Officer; EVP, General Counsel | Drug Manufacturers - General | OPT+S | $119.15 | 121,573 | $14,485,690 | 68,916 | -63.8% |
| 2026-02-10 00:04 | 2026-02-09 | MRK | Merck & Co., Inc. | Guindo Chirfi | Officer; Chief Marketing Officer | Drug Manufacturers - General | SALE | $118.41 | 10,000 | $1,184,101 | 70,615 | -12.4% |
| 2026-02-07 00:18 | 2026-02-04 | MRK | Merck & Co., Inc. | Smart Dalton E. III | Officer; SVP Fin. - Global Controller | Drug Manufacturers - General | OPT+S | $119.68 | 6,400 | $765,920 | 8,205 | -43.8% |
| 2026-02-07 00:15 | 2026-02-06 | MRK | Merck & Co., Inc. | Oosthuizen Johannes Jacobus | Officer; President, U.S. Market | Drug Manufacturers - General | SALE | $121.87 | 15,000 | $1,827,992 | 21,197 | -41.4% |
| 2026-02-07 00:13 | 2026-02-04 | MRK | Merck & Co., Inc. | Litchfield Caroline | Officer; EVP & CFO | Drug Manufacturers - General | OPT+S | $119.61 | 41,997 | $5,023,312 | 90,192 | -31.8% |
Strategic Analysis
Analyzing insider transactions within the Drug Manufacturers - General sector provides critical insights into institutional sentiment. When multiple executives across different companies in the same industry exhibit similar buying patterns (cluster buying), it often signals an upcoming sector-wide recovery or undervalued market conditions.
Regulatory Transparency
Our platform tracks SEC Form 4 filings in real-time. We differentiate between routine option exercises and open-market purchases to give you a clear view of "Skin in the Game". Understanding the roles of Directors vs. 10% Owners helps prioritize signals that carry the most predictive weight.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.